Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. Kanellakis (Oxford, United Kingdom), J. Wrightson (Oxford, United Kingdom), R. Hallifax (Oxford, United Kingdom), R. Mercer (Oxford, United Kingdom), M. Fayed (Oxford, United Kingdom), R. Asciak (Oxford, United Kingdom), I. Psallidas (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom). The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients.. 5456

Member's Comments

No comment yet.

Related content which might interest you: Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019 Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection Source: ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019 Year: 2019 Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNAse) for pleural infection in an Asian population: Similar outcomes between 5mg and 10mg regimen Source: International Congress 2018 – Clinical challenges in respiratory infection Year: 2018 Effectiveness and safety of tissue plasminogen activators (t-PA) in complicated pleural effusion (CPE), what the correlation with time it stays in the pleural space? Source: Annual Congress 2013 –A modern approach to lung diseases: from bronchi to pleura Year: 2013 The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space Source: ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020 Year: 2020 An international survey on the use of intrapleural tissue plasminogen activator/DNase therapy for pleural infection Source: ERJ Open Res, 8 (1) 00590-2021; 10.1183/23120541.00590-2021 Year: 2022 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010 SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor growth and lung metastasis formation probably through the reduction of tumor angiogenesis Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Intrapleural use of dornase alfa and tissue plasminogen activator are successful as treatment in pediatric empyema: a pilot study Source: International Congress 2018 – Paediatric respiratory infections: mechanistic insights and clinical outcomes Year: 2018 Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1 Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury Year: 2009 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Plasminogen activator inhibitor type 1 (PAI-1) is a negative regulator of lung cancer cells growth due to its anti-proteinase activity Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008